MERZ

31.1.2020 09:04:13 CET | Business Wire | Press release

Merz Aesthetics Presents Data at the IMCAS World Congress 2020

Merz, a global leader in medical aesthetics, announced today that data on the Merz Aesthetics product portfolio, including Belotero^® , Cellfina^® and Radiesse^® will be featured in oral and poster presentations at the 2020 International Master Course on Aging Science (IMCAS) World Congress, to be held from 30 January to 1 February 2020 in Paris, France.

“This meeting provides a platform for Merz Aesthetics to not only foster education and continuous training but also, to engage in thoughtful industry conversations while connecting with medical aesthetics physicians and fellow industry leaders from around the world,” said Bob Rhatigan, CEO of Merz Aesthetics. “We are grateful that our heritage and innovation in this space allows us to partner with world-renowned medical aesthetic experts, to share research on the diversified Merz Aesthetics product portfolio at the IMCAS World Congress.”

In addition to the poster presentations listed below, Merz Aesthetics is sponsoring the symposium event “Facial Rejuvenation: Interactive Sessions to Level-Up Your Injection Skills”, to be held on Saturday, 1 February at 10.30h – 12.30h, Room Amphi Bleu . The session will be opened by Bob Rhatigan, CEO of Merz Aesthetics and will include treatment insights from four international expert speakers:

Dr. Tatjana Pavicic – Dermatologist, Germany
Dr. Kate Goldie – Aesthetic Physician, United Kingdom
Prof. Yana Yutskovskaya – Dermatologist, Russia
Dr. Jani van Loghem – Aesthetic Physician, Netherlands

Oral Presentations

Independent presentations including data on the Merz Aesthetics portfolio:

What’s new in minimally invasive treatments

Update on dermal fillers (99921) – Kate Goldie, MBChB – UK. Thursday, 30 January, 17.54 – 18.06h, Amphi Bleu – Level 2

Body shaping and cellulite

Cellulite and skin laxity (93276). Doris Hexsel, Dermatologist – Brazil. Thursday, 30 January, 10.30 – 10.42h, Amphi Bleu – Level 2
Cellulite treatment update: how dimples, laxity and volume can be effectively treated (98147)¹ . Gabriela Casabona, MD– Spain. Thursday, 30 January, 11.18 – 11.30h, Amphi Bleu – Level 2

Biostimulatory fillers

Biostimulators: how dilution/diffusion interferes with outcome (93391). Gabriela Casabona, MD – Spain. Saturday, 1 February, 16.30 – 16.42, Room 143 - Level 1

E-Poster Presentations

E-Posters will be available for viewing at the Poster Zone on Level 2 , from Thursday, 30 January to Saturday, 1 February 2020 .

Distribution of cohesive polydensified matrix cross-linked hyaluronic acid volumizing gel in ex vivo human skin model. Christina Wollenburg, Jeanette Simon, Dr. Kay Marquardt, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
Calcium hydroxylapatite microspheres provide organization into unorganized collagen networks leading to improvement of skin attractiveness. Gabriela Casabona, MD – Spain. Dr. Bartosch Nowag, Daniela Schäfer, Davide Greco, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.

BOCOUTURE^® Milestone

This year, Merz is also celebrating the ten-year anniversary of BOCOUTURE^® (incobotulinumtoxin A) in Europe. The botulinum toxin is part of the Merz Aesthetics portfolio and has received approval in 15 countries in Europe within the last ten years. A Booth Talk about “BOCOUTURE^® - 10 Years of a Unique Neurotoxin” with Dr. Thomas Rappl will take place Friday, 31 January, 16.00, Booth N° P251 .

About Merz

Merz is a global, diversified healthcare company based in Frankfurt, Germany. Privately-held for more than 111 years, the company operates in the areas of aesthetics, therapeutics and consumer care and is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In fiscal year 2018/19, Merz generated revenue of EUR 1,094 million; the company has a total workforce of 3,213 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com .

¹ Merz supported Investigator Initiated Trials

View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005133/en/

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm

SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release

SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1

Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 17:20:00 CEST | Press release

Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis

Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release

Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment

OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release

NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom